NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity-Reference-Cited by-同舟云学术

NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity

Published:2024-08-08 Issue:10 Volume:73 Page:
ISSN:1432-0851
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Herault Aurelie,Mak Judy,de la Cruz-Chuh Josefa,Dillon Michael A.,Ellerman Diego,Go MaryAnn,Cosino Ely,Clark Robyn,Carson Emily,Yeung Stacey,Pichery Melanie,Gador Mylène,Chiang Eugene Y.,Wu Jia,Liang Yuxin,Modrusan Zora,Gampa Gautham,Sudhamsu Jawahar,Kemball Christopher C.,Cheung Victoria,Nguyen Thi Thu Thao,Seshasayee Dhaya,Piskol Robert,Totpal Klara,Yu Shang-Fan,Lee Genee,Kozak Katherine R.,Spiess Christoph,Walsh Kevin B.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00262-024-03795-2.pdf

Reference59 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

2. Eiger D, Ponde NF, de Azambuja E (2019) Pertuzumab in HER2-positive early breast cancer: current use and perspectives. Future Oncol 15:1823–1843. https://doi.org/10.2217/fon-2018-0896

3. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM (1993) Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255–263. https://doi.org/10.1007/BF01518520

4. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69:9330–9336. https://doi.org/10.1158/0008-5472.CAN-08-4597

5. Bang YJ, Giaccone G, Im SA et al (2017) First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol 28:855–861. https://doi.org/10.1093/annonc/mdx002